GT Biopharma Inc
GTBP
Market Cap$4.42M
Close$
$0.76
75.7% downside
Current Fair Value
75.7% downsideOvervalued by 75.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.42 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.0 |
| Outstanding Shares | 1,416,651 |
| Avg 30 Day Volume | 7,598 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About GT Biopharma Inc
2,018 employees
CEO: Anthony Cataldo GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is desig...